Cellestia is actively engaged in clinical development of first-in-class targeted therapeutics with untapped mode of action, to address unmet medical need in patients with oncology and immunological disorders.
Develop CB-103, a novel, first-in-class, oral pan-NOTCH inhibitor with a unique mode of action for treatment of NOTCH dependent leukemias, lymphomas and solid tumors.
Cellestia Biotech AG was founded in 2014 as a spin-off from EPFL (Ecole Polytechnique Fédérale de Lausanne, Switzerland). Cellestia`s pipeline including lead candidate, oral small molecule CB-103 is based on proprietary know-how and more than two decades of research in Prof. Radtke´s laboratory at Swiss Institute for Experimental Cancer Research (ISREC) at EPFL. Prof. Freddy Radtke is an internationally recognized key opinion leader in NOTCH pathway and cancer stem cells research. Dr. Rajwinder Lehal, CSO, has established Cellestia’s drug discovery platform and leading the early development phase of the program for a decade.
In October 2015, a team of senior pharma executives joined the company as investors and co-founders, including Michael Bauer, PhD, as CEO. An experienced drug development executive who has worked in senior management positions in Pharma and Biotech companies.
Additional co-founders joining Cellestia have completed the Cellestia development team providing in-depth experience in regulatory affairs, business and corporate development, as well as IP and legal affairs.
The founding team’s successful track record in respective disciplines offers a unique blend of academic excellence, pharma drug development, regulatory and business competences, that is a pre-requisite for a successful drug development company.
Cellestia Biotech’s research activities are conducted at EPFL laboratories, Lausanne, Switzerland and several other reputed international research institutions. In addition, a high-profile panel of strategic advisors and experts has been engaged. A Clinical Advisory Board with internationally recognized clinicians from worldwide leading oncology hospitals and further research collaborations in preparation of clinical development has been established.